Medical management of colorectal Crohn's disease

Current Opinion in Gastroenterology

Volumn 12, Issue 1, 1996, Pages 26-31

  Barnett, Jeffrey L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

COLON CROHN DISEASE; HUMAN; NAUSEA; NEPHROTOXICITY; REVIEW; SIDE EFFECT;

EID: 0029869925     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199601000-00006     Document Type: Review

References (59)

1. O'Morain C, Segal AW, Levi AJ: Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. BMJ 1984, 288:1859-1862.
2. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995, 108:1056-1067. A carefully detailed analysis and review comparing the efficacy of enteral nutrition with that of corticosteroids and of elemental to nonelemental formulas.
3. Mansfield JC, Giaffer MH, Holdsworth CD: Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut 1995, 36:60-66.
4. Ruuska T, Savilahti E, Maki M, Ormala T, Visakorpi JK: Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 1994, 19:175-180.
5. Papadopoulou A, Rawashdeh MO, Brown GA, McNeish AS, Booth IW: Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr 1995, 84:79-83.
6. Wu S, Craig RM: Intense nutritional support in inflammatory bowel disease. Dig Dis Sci 1995, 40:843-852. This review discusses the theoretical basis for various enteral and parenteral supports and summarizes available data using these diets. Included is a critical analysis of the guidelines American Society of Parenteral and Enteral Nutrition.
7. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E: Metronidazole in Crohn's disease. Scand J Gastroenterol 1978, 13:123-127.
8. Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perianal Crohn's disease with metronidazole. Gastroenterology 1980, 795:357-365.
9. Ursing B, Alm T, Barany F, Bergelin I, Gamot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, et al.: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II: results. Gastroenterology 1982, 83:550-562.
10. Jackobovits J, Schuster MM: Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984, 79:533-540.
11. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al.: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32:1071-1075.
12. Prantera C, Kolm A, Zannoni F, Spimpolo N, Bonfa M: Metronidazole plus ciprofloxacin in the treatment of active refractory Crohn's disease: results of an open study. J Clin Gastroenterol 1994, 19:79-88.
13. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995, 108:1617-1621. The first controlled trial to use antibiotics for prophylaxis after surgical resection for ileal Crohn's disease.
14. Present DH: The prevention of Crohn's disease after surgery. metronidazole is a small but continuous medical advancement [editorial]. Gastroenterology 1995, 108:1935-1938. This editorial succinctly reviews the use of medical therapy to maintain remission after medical or surgical therapy for Crohn's disease.
15. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National Cooperative Crohn's Disease Study: results of drug treatment Gastroenterology 1979, 77:847-869.
16. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment Gastroenterology 1984, 86:249-266.
17. Rasmussen SN, Lauritsen K, Tage-Jensen U, Nielsen OH, Bytzer P, Jacobsan O, Ladefoged K, Vilien M, Binder V, Rask-Madsen J, et al.: 5-Aminosalicylic acid in the treatment of Crohn's disease: a 16-week double-blind, placebo-controlled multicenter study with Pentasa. Scand J Gastroenterol 1987, 22:877-883.
18. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL, the Pentasa Crohn's Disease Study Group: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993, 104:1293-1301.
19. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR: A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994, 19:278-282. Despite a high dropout rate, this controlled study supports the utility of mesalamine for mildly to moderately active Crohn's colitis and ileocolitis.
20. Singleton JW, Hanauer S, Robinson M: Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995, 40:931-935. Mesalamine improves not only symptoms but also such quality-of-life measures as ability to sleep, outdoor activities, sexual relationships, social activities, and ability to work in patients with mildly to moderately active Crohn's disease.
21. Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:2116-2123. This and another meta-analysis (Messori et al., Am J Gastroenterol 1994, 89:692-698) confirm the efficacy of the 5-ASA drugs for the maintenance of remission in Crohn's disease.
22. Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:2116-2123. This and another meta-analysis (Messori et al., Am J Gastroenterol 1994, 89:692-698) confirm the efficacy of the 5-ASA drugs for the maintenance of remission in Crohn's disease.
23. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloti C, d'Albasio G, DeSimone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:692-698. This and another meta-analysis (Steinhart et al., Am J Gastroenterol 1994, 89:2116-2123) confirm the efficacy of 5-ASA drugs for the maintenance of remission in Crohn's disease. Included is an estimate of the cost required to prevent a relapse.
24. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloti C, d'Albasio G, DeSimone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:692-698. This and another meta-analysis (Steinhart et al., Am J Gastroenterol 1994, 89:2116-2123) confirm the efficacy of 5-ASA drugs for the maintenance of remission in Crohn's disease. Included is an estimate of the cost required to prevent a relapse.
25. Schreiber A, Howaldt S, Raedler A: Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets: double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Gut 1994, 35:1081-1085. This comparison of the 5-ASA and 4-ASA drugs shows near equivalency, although the dose used was low. The theoretical advantage of 4-ASA over 5-ASA is reviewed.
26. Caprilli R, Andreoli A, Capurso L, Corrao G, d'Albasio G, Gioieni A, Lanfranchi GA, Paladini I, Pallone F, Ponti V, et al., The Gruppo Italiano Per Lo Studio Del Colon E Del Retto (GISC): Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994, 8:35-43. Interim results of a long-term multicenter study (not placebo controlled) that will help to define the role of long-term 5-ASA drug therapy after resection.
27. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, d'Arienzo A, d'Albasio G, Pennestri D, The Italian Cooperative Study Group: Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995, 108:345-349. This placebo-controlled, blinded study confirms the utility of Pentasa as a prophylactic agent after resection for Crohn's disease. A reduction in the endoscopic but not clinical relapse rate could be shown.
28. McLeod RS, Wolff BG, Steinhart H, Carryer P, Andrews D, Blair J, Cargeni J, Cohen Z, Cullen J, Chaytor R, et al.: Delayed recurrence following surgery for Crohn's disease (CD) [abstract]. Gastroenterology 1994, 106:733.
29. Sachar DB: Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995, 20:117-122. A comprehensive review of available drug therapies to prevent relapse in patients with inflammatory bowel disease.
30. McLeod RS: Medical prophylaxis is indicated for the prevention of recurrence of Crohn's disease after surgery. Inflammatory Bowel Disease 1995, 1:159-161. Critically reviews the issue of medical prophylaxis.
31. Peppercorn MA: Should all Crohn's patients receive prophylactic medication after surgical resection? No. Inflammatory Bowel Disease 1995, 1:162-164. Critically reviews the issue of medical prophylaxis.
32. Banks PA, Present DH: Is medical prophylaxis indicated for the prevention of recurrence of Crohn's disease after surgery? Inflammatory Bowel Disease 1995, 1:165.
33. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, William CN, Nilsson LG, Persson T, The Canadian Inflammatory Bowel Disease Study Group: Oral budesonide for active Crohn's disease. N Engl J Med 1994, 331:836-841. Compares budesonide with placebo or steroids in large, well-controlled, carefully performed studies.
34. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewel D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, et al.: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845. Compares budesonide with placebo or steroids in large, well-controlled, carefully performed studies.
35. Sachar DB: Budesonide for inflammatory bowel disease. N Engl J Med 1994, 331:873-874. The author critiques the articles by Greenberg et al. (N Engl J Med 1994, 331:836-841) and Rutgeerts et al. (N Engl J Med 1994, 331:842-845) and discusses budesonide and corticosteroids in the management of inflammatory bowel disease.
36. Sachar DB: Budesonide for inflammatory bowel disease. N Engl J Med 1994, 331:873-874. The author critiques the articles by Greenberg et al. (N Engl J Med 1994, 331:836-841) and Rutgeerts et al. (N Engl J Med 1994, 331:842-845) and discusses budesonide and corticosteroids in the management of inflammatory bowel disease.
37. Sachar DB: Budesonide for inflammatory bowel disease. N Engl J Med 1994, 331:873-874. The author critiques the articles by Greenberg et al. (N Engl J Med 1994, 331:836-841) and Rutgeerts et al. (N Engl J Med 1994, 331:842-845) and discusses budesonide and corticosteroids in the management of inflammatory bowel disease.
38. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky de Meckadell O, Williams N, MacDonald AS, Tanton R, Molina F, Campanini MC, et al.: A placebo-controlled, double-blind randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989, 321:845-850.
39. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky de Meckadell O, Williams N, MacDonald AS, Tanton R, Molina F, Campanini MC, et al.: Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991, 26:689-695.
40. Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, et al.: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994, 330:1846-1851.
41. Jewell DP, Lennard-Jones JE, the Cyclosporin Study Group of Great Britain and Ireland: Oral cyclosporin for chronic active Crohn's disease: a multicenter controlled trial. Eur J Gastroenterol Hepatol 1994, 6:499-505.
42. Nicholls S, Domizio P, Wiliams CB, Dawnay A, Braegger CP, MacDonald TT, Walker-Smith JA: Cyclosporin as initial treatment for Crohn's disease. Arch Dis Child 1994, 71:243-247. This small 8-week trial found no advantages for cyclosporine over steroids in children with active Crohn's disease.
43. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Disease 1995, 1:48-63. An excellent review on the subject.
44. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
45. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, et al., the North American Crohn's Study Group Investigators: Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995, 332:292-297. Well-designed 16-week study shows that 25 mg of parenteral methotrexate is more effective than placebo in patients with active, steroid-requiring Crohn's disease.
46. Davidsen B, Munkholm P, Schlichting P, Nielsen OH, Krarup NH, Bonnevie-Nielsen V: Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther 1995, 9:75-79.
47. Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H: Prospective evaluation of interferon-α in treatment of chronic active Crohn's disease. Dig Dis Sci 1995, 40:800-804.
48. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995, 122:132-142. An important analysis of available randomized trials using azathioprine and 6-mercaptopurine for active, quiescent, and fistulous disease. Dosages, onset of action, and adverse effects are also explored.
49. Bicks RC, Groshart KW, Chandler RW: The treatment of severe chronically active Crohn's disease by T8 (suppressor cell) lymphapheresis [abstract]. Gastroenterology 1985, 88:1325.
50. Bicks RO, Groshart K, Chandler R: The treatment of severe chronically active Crohn's disease by T lymphocyte apheresis [abstract]. Gastroenterology 1986, 90:1346.
51. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, Rene E, Soule JC, the Group d-Etudes Therapeutiques Des Affections Inflammatoires Digestives: Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial [editorial]. Gastroenterology 1994, 107:357-361. In Crohn's patients with a steroid-induced remission, lymphocyte apheresis does not appear to be a useful therapy to prevent subsequent attacks. This editorial and the letter from Chadwick (Gastroenterology 1994, 107:579-589) offer more insight into this therapy.
52. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, Rene E, Soule JC, the Group d-Etudes Therapeutiques Des Affections Inflammatoires Digestives: Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial [editorial]. Gastroenterology 1994, 107:357-361. In Crohn's patients with a steroid-induced remission, lymphocyte apheresis does not appear to be a useful therapy to prevent subsequent attacks. This editorial and the letter from Chadwick (Gastroenterology 1994, 107:579-589) offer more insight into this therapy.
53. Chadwick VS: Lymphocyte apheresis in Crohn's disease [letter]. Gastroenterology 1994, 107:579-589.
54. Bicks RO, Groshart KD: Tempest about T-lymphocyte apheresis in Crohn's disease. Gastroenterology 1994, 108:952-953.
55. Ainley CC, Cason J, Carlsson LK, Slavin BM, Thompson RPH: Zinc status in inflammatory bowel disease. Clin Sci 1988, 75:277-283.
56. Mulder TPJ, Verspaget HW, Janssens AR, de Bruin PAF, Pena AS, Lamers CBHW: Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut 1991, 32:1146-1150.
57. Mulder TPJ, Van Der Slys Veer A, Verspaget HW, Griffioen G, Pena AS, Janssens AR, Lamers CBHW: Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepalol 1994, 9:472-477.
58. Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S: Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 1994, 19:202-205.
59. Colombel JF, Mathieu D, Bouault JM, Lesage X, Zavadil P, Quandalle P, Cortot A: Hyperbaric oxygenation in severe perineal Crohn's disease. Dis Colon Rectum 1995, 38:609-614. This small open trial establishes a potential role for hyperbaric oxygen therapy for perineal Crohn's disease.